Now showing items 1-20 of 47

    • A comparison of the diagnostic value of MRI and <sup>18</sup>F-FDG-PET/CT in suspected spondylodiscitis. 

      Smids, C; Kouijzer, IJE; Vos, FJ; Sprong, T; Hosman, AJF; de Rooy, JWJ; Aarntzen, EHJG; de Geus-Oei, L-F; Oyen, WJG; Bleeker-Rovers, CP (2017-02)
      Purpose The purpose of this study was to evaluate the diagnostic value of <sup>18</sup>F-fluorodeoxyglucose (FDG) positron emission tomography and computed tomography (PET/CT scan) and magnetic resonance imaging (MRI) in ...
    • A randomized phase III study of 72 h infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3). 

      Shamash, J; Sarker, S-J; Huddart, R; Harland, S; Joffe, JK; Mazhar, D; Birtle, A; White, J; Chowdhury, K; Wilson, P; Marshall, MR; Vinnicombe, S (2017-06)
      Background Bleomycin is an integral part of combination chemotherapy in germ cell tumours. Pulmonary toxicity often necessitates drug cessation and death occurs in 1%-2% of patients. A continuous infusion of bleomycin might ...
    • A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations. 

      George, SL; Izquierdo, E; Campbell, J; Koutroumanidou, E; Proszek, P; Jamal, S; Hughes, D; Yuan, L; Marshall, LV; Carceller, F; Chisholm, JC; Vaidya, S; Mandeville, H; Angelini, P; Wasti, A; Bexelius, T; Thway, K; Gatz, SA; Clarke, M; Al-Lazikani, B; Barone, G; Anderson, J; Tweddle, DA; Gonzalez, D; Walker, BA; Barton, J; Depani, S; Eze, J; Ahmed, SW; Moreno, L; Pearson, A; Shipley, J; Jones, C; Hargrave, D; Jacques, TS; Hubank, M; Chesler, L (2019-11)
      BACKGROUND:For children with cancer, the clinical integration of precision medicine to enable predictive biomarker-based therapeutic stratification is urgently needed. METHODS:We have developed a hybrid-capture next-generation ...
    • Abscopal effect of radiotherapy in a patient with metastatic diffuse-type giant cell tumor. 

      Desar, IME; Braam, PM; Kaal, SEJ; Gerritsen, WR; Oyen, WJG; van der Graaf, WTA (2016-12)
    • Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors. 

      Abu Zaid, M; Dinh, PC; Monahan, PO; Fung, C; El-Charif, O; Feldman, DR; Hamilton, RJ; Vaughn, DJ; Beard, CJ; Cook, R; Althouse, S; Ardeshir-Rouhani-Fard, S; Sesso, HD; Huddart, R; Mushiroda, T; Kubo, M; Dolan, ME; Einhorn, LH; Fossa, SD; Travis, LB; Platinum Study Group (2019-05)
      Background This study examined the prevalence of hypogonadism, its clinical and genetic risk factors, and its relationship to adverse health outcomes (AHOs) in North American testicular cancer survivors (TCS) after modern ...
    • Association between Adult Height and Risk of Colorectal, Lung, and Prostate Cancer: Results from Meta-analyses of Prospective Studies and Mendelian Randomization Analyses. 

      Khankari, NK; Shu, X-O; Wen, W; Kraft, P; Lindström, S; Peters, U; Schildkraut, J; Schumacher, F; Bofetta, P; Risch, A; Bickeböller, H; Amos, CI; Easton, D; Eeles, RA; Eeles, RA; Gruber, SB; Haiman, CA; Hunter, DJ; Chanock, SJ; Pierce, BL; Zheng, W; Colorectal Transdisciplinary Study (CORECT); Discovery, Biology, and Risk of Inherited Variants in Breast Cancer (DRIVE); Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE); Transdisciplinary Research in Cancer of the Lung (TRICL) (2016-09-06)
      Background Observational studies examining associations between adult height and risk of colorectal, prostate, and lung cancers have generated mixed results. We conducted meta-analyses using data from prospective cohort ...
    • Association of Body Mass Index and Age With Subsequent Breast Cancer Risk in Premenopausal Women. 

      Premenopausal Breast Cancer Collaborative Group; Schoemaker, MJ; Nichols, HB; Wright, LB; Brook, MN; Jones, ME; O'Brien, KM; Adami, H-O; Baglietto, L; Bernstein, L; Bertrand, KA; Boutron-Ruault, M-C; Braaten, T; Chen, Y; Connor, AE; Dorronsoro, M; Dossus, L; Eliassen, AH; Giles, GG; Hankinson, SE; Kaaks, R; Key, TJ; Kirsh, VA; Kitahara, CM; Koh, W-P; Larsson, SC; Linet, MS; Ma, H; Masala, G; Merritt, MA; Milne, RL; Overvad, K; Ozasa, K; Palmer, JR; Peeters, PH; Riboli, E; Rohan, TE; Sadakane, A; Sund, M; Tamimi, RM; Trichopoulou, A; Ursin, G; Vatten, L; Visvanathan, K; Weiderpass, E; Willett, WC; Wolk, A; Yuan, J-M; Zeleniuch-Jacquotte, A; Sandler, DP; Swerdlow, AJ (2018-11-08)
      Importance The association between increasing body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) and risk of breast cancer is unique in cancer epidemiology in that a crossover ...
    • Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. 

      Patel, VL; Busch, EL; Friebel, TM; Cronin, A; Leslie, G; McGuffog, L; Adlard, J; Agata, S; Agnarsson, BA; Ahmed, M; Aittomäki, K; Alducci, E; Andrulis, IL; Arason, A; Arnold, N; Artioli, G; Arver, B; Auber, B; Azzollini, J; Balmaña, J; Barkardottir, RB; Barnes, DR; Barroso, A; Barrowdale, D; Belotti, M; Benitez, J; Bertelsen, B; Blok, MJ; Bodrogi, I; Bonadona, V; Bonanni, B; Bondavalli, D; Boonen, SE; Borde, J; Borg, A; Bradbury, AR; Brady, A; Brewer, C; Brunet, J; Buecher, B; Buys, SS; Cabezas-Camarero, S; Caldés, T; Caliebe, A; Caligo, MA; Calvello, M; Campbell, IG; Carnevali, I; Carrasco, E; Chan, TL; Chu, ATW; Chung, WK; Claes, KBM; Collaborators, GS; Collaborators, E; Cook, J; Cortesi, L; Couch, FJ; Daly, MB; Damante, G; Darder, E; Davidson, R; de la Hoya, M; Puppa, LD; Dennis, J; Díez, O; Ding, YC; Ditsch, N; Domchek, SM; Donaldson, A; Dworniczak, B; Easton, DF; Eccles, DM; Eeles, RA; Ehrencrona, H; Ejlertsen, B; Engel, C; Evans, DG; Faivre, L; Faust, U; Feliubadaló, L; Foretova, L; Fostira, F; Fountzilas, G; Frost, D; García-Barberán, V; Garre, P; Gauthier-Villars, M; Géczi, L; Gehrig, A; Gerdes, A-M; Gesta, P; Giannini, G; Glendon, G; Godwin, AK; Goldgar, DE; Greene, MH; Gutierrez-Barrera, AM; Hahnen, E; Hamann, U; Hauke, J; Herold, N; Hogervorst, FBL; Honisch, E; Hopper, JL; Hulick, PJ; Investigators, K; Investigators, H; Izatt, L; Jager, A; James, P; Janavicius, R; Jensen, UB; Jensen, TD; Johannsson, OT; John, EM; Joseph, V; Kang, E; Kast, K; Kiiski, JI; Kim, S-W; Kim, Z; Ko, K-P; Konstantopoulou, I; Kramer, G; Krogh, L; Kruse, TA; Kwong, A; Larsen, M; Lasset, C; Lautrup, C; Lazaro, C; Lee, J; Lee, JW; Lee, MH; Lemke, J; Lesueur, F; Liljegren, A; Lindblom, A; Llovet, P; Lopez-Fernández, A; Lopez-Perolio, I; Lorca, V; Loud, JT; Ma, ESK; Mai, PL; Manoukian, S; Mari, V; Martin, L; Matricardi, L; Mebirouk, N; Medici, V; Meijers-Heijboer, HEJ; Meindl, A; Mensenkamp, AR; Miller, C; Gomes, DM; Montagna, M; Mooij, TM; Moserle, L; Mouret-Fourme, E; Mulligan, AM; Nathanson, KL; Navratilova, M; Nevanlinna, H; Niederacher, D; Nielsen, FCC; Nikitina-Zake, L; Offit, K; Olah, E; Olopade, OI; Ong, K-R; Osorio, A; Ott, C-E; Palli, D; Park, SK; Parsons, MT; Pedersen, IS; Peissel, B; Peixoto, A; Pérez-Segura, P; Peterlongo, P; Petersen, AH; Porteous, ME; Pujana, MA; Radice, P; Ramser, J; Rantala, J; Rashid, MU; Rhiem, K; Rizzolo, P; Robson, ME; Rookus, MA; Rossing, CM; Ruddy, KJ; Santos, C; Saule, C; Scarpitta, R; Schmutzler, RK; Schuster, H; Senter, L; Seynaeve, CM; Shah, PD; Sharma, P; Shin, VY; Silvestri, V; Simard, J; Singer, CF; Skytte, A-B; Snape, K; Solano, AR; Soucy, P; Southey, MC; Spurdle, AB; Steele, L; Steinemann, D; Stoppa-Lyonnet, D; Stradella, A; Sunde, L; Sutter, C; Tan, YY; Teixeira, MR; Teo, SH; Thomassen, M; Tibiletti, MG; Tischkowitz, M; Tognazzo, S; Toland, AE; Tommasi, S; Torres, D; Toss, A; Trainer, AH; Tung, N; van Asperen, CJ; van der Baan, FH; van der Kolk, LE; van der Luijt, RB; van Hest, LP; Varesco, L; Varon-Mateeva, R; Viel, A; Vierstraete, J; Villa, R; von Wachenfeldt, A; Wagner, P; Wang-Gohrke, S; Wappenschmidt, B; Weitzel, JN; Wieme, G; Yadav, S; Yannoukakos, D; Yoon, S-Y; Zanzottera, C; Zorn, KK; D'Amico, AV; Freedman, ML; Pomerantz, MM; Chenevix-Trench, G; Antoniou, AC; Neuhausen, SL; Ottini, L; Nielsen, HR; Rebbeck, TR (2020-02)
      Pathogenic sequence variants (PSV) in <i>BRCA1</i> or <i>BRCA2</i> (<i>BRCA1/2</i>) are associated with increased risk and severity of prostate cancer. We evaluated whether PSVs in <i>BRCA1/2</i> were associated with risk ...
    • Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls. 

      Saya, S; Killick, E; Thomas, S; Taylor, N; Bancroft, EK; Rothwell, J; Benafif, S; Dias, A; Mikropoulos, C; Pope, J; Chamberlain, A; Gunapala, R; SIGNIFY Study Steering Committee; Izatt, L; Side, L; Walker, L; Tomkins, S; Cook, J; Barwell, J; Wiles, V; Limb, L; Eccles, D; Leach, MO; Shanley, S; Gilbert, FJ; Hanson, H; Gallagher, D; Rajashanker, B; Whitehouse, RW; Koh, D-M; Sohaib, SA; Evans, DG; Eeles, RA (2017-07)
      In the United Kingdom, current screening guidelines for TP53 germline mutation carriers solely recommends annual breast MRI, despite the wide spectrum of malignancies typically seen in this group. This study sought to ...
    • Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis. 

      Ballinger, ML; Best, A; Mai, PL; Khincha, PP; Loud, JT; Peters, JA; Achatz, MI; Chojniak, R; Balieiro da Costa, A; Santiago, KM; Garber, J; O'Neill, AF; Eeles, RA; Evans, DG; Bleiker, E; Sonke, GS; Ruijs, M; Loo, C; Schiffman, J; Naumer, A; Kohlmann, W; Strong, LC; Bojadzieva, J; Malkin, D; Rednam, SP; Stoffel, EM; Koeppe, E; Weitzel, JN; Slavin, TP; Nehoray, B; Robson, M; Walsh, M; Manelli, L; Villani, A; Thomas, DM; Savage, SA (2017-12)
      Importance Guidelines for clinical management in Li-Fraumeni syndrome, a multiple-organ cancer predisposition condition, are limited. Whole-body magnetic resonance imaging (WBMRI) may play a role in surveillance of this ...
    • Breast Cancer Risk After Recent Childbirth: A Pooled Analysis of 15 Prospective Studies. 

      Nichols, HB; Schoemaker, MJ; Cai, J; Xu, J; Wright, LB; Brook, MN; Jones, ME; Adami, H-O; Baglietto, L; Bertrand, KA; Blot, WJ; Boutron-Ruault, M-C; Dorronsoro, M; Dossus, L; Eliassen, AH; Giles, GG; Gram, IT; Hankinson, SE; Hoffman-Bolton, J; Kaaks, R; Key, TJ; Kitahara, CM; Larsson, SC; Linet, M; Merritt, MA; Milne, RL; Pala, V; Palmer, JR; Peeters, PH; Riboli, E; Sund, M; Tamimi, RM; Tjønneland, A; Trichopoulou, A; Ursin, G; Vatten, L; Visvanathan, K; Weiderpass, E; Wolk, A; Zheng, W; Weinberg, CR; Swerdlow, AJ; Sandler, DP (2019-01)
      Background Parity is widely recognized as protective for breast cancer, but breast cancer risk may be increased shortly after childbirth. Whether this risk varies with breastfeeding, family history of breast cancer, or ...
    • Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. 

      Peterlongo, P; Chang-Claude, J; Moysich, KB; Rudolph, A; Schmutzler, RK; Simard, J; Soucy, P; Eeles, RA; Easton, DF; Hamann, U; Wilkening, S; Chen, B; Rookus, MA; Schmidt, MK; van der Baan, FH; Spurdle, AB; Walker, LC; Lose, F; Maia, A-T; Montagna, M; Matricardi, L; Lubinski, J; Jakubowska, A; Gómez Garcia, EB; Olopade, OI; Nussbaum, RL; Nathanson, KL; Domchek, SM; Rebbeck, TR; Arun, BK; Karlan, BY; Orsulic, S; Lester, J; Chung, WK; Miron, A; Southey, MC; Goldgar, DE; Buys, SS; Janavicius, R; Dorfling, CM; van Rensburg, EJ; Ding, YC; Neuhausen, SL; Hansen, TVO; Gerdes, A-M; Ejlertsen, B; Jønson, L; Osorio, A; Martínez-Bouzas, C; Benitez, J; Conway, EE; Blazer, KR; Weitzel, JN; Manoukian, S; Peissel, B; Zaffaroni, D; Scuvera, G; Barile, M; Ficarazzi, F; Mariette, F; Fortuzzi, S; Viel, A; Giannini, G; Papi, L; Martayan, A; Tibiletti, MG; Radice, P; Vratimos, A; Fostira, F; Garber, JE; Donaldson, A; Brewer, C; Foo, C; Evans, DGR; Frost, D; Eccles, D; Brady, A; Cook, J; Tischkowitz, M; Adlard, J; Barwell, J; Walker, L; Izatt, L; Side, LE; Kennedy, MJ; Rogers, MT; Porteous, ME; Morrison, PJ; Platte, R; Davidson, R; Hodgson, SV; Ellis, S; Cole, T; EMBRACE; Godwin, AK; Claes, K; Van Maerken, T; Meindl, A; Gehrig, A; Sutter, C; Engel, C; Niederacher, D; Steinemann, D; Plendl, H; Kast, K; Rhiem, K; Ditsch, N; Arnold, N; Varon-Mateeva, R; Wappenschmidt, B; Wang-Gohrke, S; Bressac-de Paillerets, B; Buecher, B; Delnatte, C; Houdayer, C; Stoppa-Lyonnet, D; Damiola, F; Coupier, I; Barjhoux, L; Venat-Bouvet, L; Golmard, L; Boutry-Kryza, N; Sinilnikova, OM; Caron, O; Pujol, P; Mazoyer, S; Belotti, M; GEMO Study Collaborators; Piedmonte, M; Friedlander, ML; Rodriguez, GC; Copeland, LJ; de la Hoya, M; de la Hoya, M; Segura, PP; Nevanlinna, H; Aittomäki, K; van Os, TAM; Meijers-Heijboer, HEJ; van der Hout, AH; Vreeswijk, MPG; Hoogerbrugge, N; Ausems, MGEM; van Doorn, HC; Collée, JM; HEBON; Olah, E; Diez, O; Blanco, I; Lazaro, C; Brunet, J; Feliubadalo, L; Cybulski, C; Gronwald, J; Durda, K; Jaworska-Bieniek, K; Sukiennicki, G; Arason, A; Chiquette, J; Teixeira, MR; Olswold, C; Couch, FJ; Lindor, NM; Wang, X; Szabo, CI; Offit, K; Corines, M; Jacobs, L; Robson, ME; Zhang, L; Joseph, V; Joseph, V; Berger, A; Singer, CF; Rappaport, C; Kaulich, DG; Pfeiler, G; Tea, M-KM; Phelan, CM; Greene, MH; Mai, PL; Rennert, G; Mulligan, AM; Glendon, G; Tchatchou, S; Andrulis, IL; Toland, AE; Bojesen, A; Pedersen, IS; Thomassen, M; Jensen, UB; Laitman, Y; Rantala, J; von Wachenfeldt, A; Ehrencrona, H; Askmalm, MS; Borg, Å; Kuchenbaecker, KB; McGuffog, L; Barrowdale, D; Healey, S; Lee, A; Pharoah, PDP; Chenevix-Trench, G; KConFab Investigators; Antoniou, AC; Friedman, E (2015-01)
      Background BRCA1 and BRCA2 mutation carriers are at substantially increased risk for developing breast and ovarian cancer. The incomplete penetrance coupled with the variable age at diagnosis in carriers of the same mutation ...
    • Circulating Growth and Sex Hormone Levels and Breast Tissue Composition in Young Nulliparous Women. 

      Denholm, R; De Stavola, BL; Hipwell, JH; Doran, SJ; Holly, JMP; Folkerd, E; Dowsett, M; Leach, MO; Hawkes, DJ; Dos-Santos-Silva, I (2018-12)
      Background Endogenous hormones are associated with breast cancer risk, but little is known about their role on breast tissue composition, a strong risk predictor. This study aims to investigate the relationship between ...
    • Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms. 

      El Charif, O; Mapes, B; Trendowski, MR; Wheeler, HE; Wing, C; Dinh, PC; Frisina, RD; Feldman, DR; Hamilton, RJ; Vaughn, DJ; Fung, C; Kollmannsberger, C; Mushiroda, T; Kubo, M; Gamazon, ER; Cox, NJ; Huddart, R; Ardeshir-Rouhani-Fard, S; Monahan, P; Fossa, SD; Einhorn, LH; Travis, LB; Dolan, ME (2019-07)
      Purpose Cisplatin, a commonly used chemotherapeutic, results in tinnitus, the phantom perception of sound. Our purpose was to identify the clinical and genetic determinants of tinnitus among testicular cancer survivors ...
    • COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss. 

      Crabb, SJ; Martin, K; Abab, J; Ratcliffe, I; Thornton, R; Lineton, B; Ellis, M; Moody, R; Stanton, L; Galanopoulou, A; Maishman, T; Geldart, T; Bayne, M; Davies, J; Lamb, C; Popat, S; Joffe, JK; Nutting, C; Chester, J; Hartley, A; Thomas, G; Ottensmeier, C; Huddart, R; King, E (2017-12)
      Background Cisplatin is one of the most ototoxic chemotherapy drugs, resulting in a permanent and irreversible hearing loss in up to 50% of patients. Cisplatin and gentamicin are thought to damage hearing through a common ...
    • Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. 

      Hill, RM; Kuijper, S; Lindsey, JC; Petrie, K; Schwalbe, EC; Barker, K; Boult, JKR; Williamson, D; Ahmad, Z; Hallsworth, A; Ryan, SL; Poon, E; Robinson, SP; Ruddle, R; Raynaud, FI; Howell, L; Kwok, C; Joshi, A; Nicholson, SL; Crosier, S; Ellison, DW; Wharton, SB; Robson, K; Michalski, A; Hargrave, D; Jacques, TS; Pizer, B; Bailey, S; Swartling, FJ; Weiss, WA; Chesler, L; Clifford, SC (2015-01)
      We undertook a comprehensive clinical and biological investigation of serial medulloblastoma biopsies obtained at diagnosis and relapse. Combined MYC family amplifications and P53 pathway defects commonly emerged at relapse, ...
    • Comparative Validation of Breast Cancer Risk Prediction Models and Projections for Future Risk Stratification. 

      Pal Choudhury, P; Wilcox, AN; Brook, MN; Zhang, Y; Ahearn, T; Orr, N; Coulson, P; Schoemaker, MJ; Jones, ME; Gail, MH; Swerdlow, AJ; Chatterjee, N; Garcia-Closas, M (2020-03)
      Background External validation of risk models is critical for risk-stratified breast cancer prevention. We used the Individualized Coherent Absolute Risk Estimation (iCARE) as a flexible tool for risk model development and ...
    • Desmoid fibromatosis through the patients' eyes: time to change the focus and organisation of care? 

      Husson, O; Younger, E; Dunlop, A; Dean, L; Strauss, DC; Benson, C; Hayes, AJ; Miah, A; van Houdt, W; Zaidi, S; Smith, M; Williams, J; Jones, RL; van der Graaf, WTA (2019-03)
      Purpose Desmoid fibromatosis (DF) is a rare, unpredictable disease with no established, evidence-based treatments. Individual management is based on consensus algorithms. This study aimed to examine the specific health-related ...
    • Dosimetry-based treatment for Graves' disease. 

      Hyer, SL; Pratt, B; Gray, M; Chittenden, S; Du, Y; Harmer, CL; Flux, GD (2018-06)
      Objective The aim of this retrospective study was to assess the long-term outcome of a personalized dosimetry approach in Graves' disease aiming to render patients euthyroid from a planned thyroid absorbed dose of ...
    • Evaluation of dynamic contrast-enhanced MRI biomarkers for stratified cancer medicine: How do permeability and perfusion vary between human tumours? 

      Little, RA; Barjat, H; Hare, JI; Jenner, M; Watson, Y; Cheung, S; Holliday, K; Zhang, W; O'Connor, JPB; Barry, ST; Puri, S; Parker, GJM; Waterton, JC (2018-02)
      Solid tumours exhibit enhanced vessel permeability and fenestrated endothelium to varying degree, but it is unknown how this varies in patients between and within tumour types. Dynamic contrast-enhanced (DCE) MRI provides ...